Different gene delivery methods are explored, focusing on those currently in clinical trials for gene therapy in hemophilia, and questions about how the body responds to these gene transfer techniques are explained. Jan 01, 2020 adenoassociated virus aavmediated gene therapy has shown clinical benefit after 1 year of followup for patients with hemophilia a. Advances and challenges for hemophilia gene therapy human. If transferred successfully, the functional gene is intended to provide the correct instructions for the cell to make factor viii or factor ix clotting protein. Valoctocogene roxaparvovec bmn 270 for hemophilia a. The recent success of earlyphase clinical trials for adenoassociated viral aav liverdirected gene therapy for hemophilia b hb demonstrates the potential for gene therapy, in the future, to succeed proteinbased prophylaxis therapy for hb. Aav5factor viii gene transfer in severe hemophilia a nejm. Gene therapy aims to achieve this by using two comple. Interactive features, such as clickable slideshows, popup notes, and icons containing essential information make the learning experience fun and engaging. Significant obstacles, however, need to be overcome prior to widespread adoption. Gene therapy corrects factor viii levels in hemophilia a. The document was approved by the medical and scientific advisory council masac of the national hemophilia foundation nhf on november 21, 2018, and adopted by.
Gene therapy in patients with severe hemophilia a video summary of original article dec 28, 2017 aav5factor viii gene transfer in severe hemophilia a s. Even six years ago, gene therapy for hemophilia was a tantalizing promise. Hemophilia provides an attractive target for gene therapy studies. Gene therapy for hemophilia hematologyoncology clinics. Quick take gene therapy for factor ix deficiency 01. Hemophilia b gene therapy with a highspecificactivity. Therefore, exchanging the defective gene for a functional replacement could potentially reverse the disease and eliminate the need for factor replacement therapy. Its not available yet, but after 20 years in development. The document was approved by the medical and scientific advisory council masac of the national hemophilia foundation nhf on november 21, 2018, and adopted by the nhf board of. Jan 31, 2019 aav vector liver directed gene therapy in hemophilia animal models induces immune tolerance to fviii and fix through induction of factorspecific regulatory t cells treg. Aavbased gene therapy is one of a number of novel approaches for treatment of hemophilia with other gene therapy in vivo and ex vivo. Given the intrinsic limitations of pst, there is still a need to develop a longterm cure for hemophilia via gene therapy. The onetime treatments seek to fight the disease by adding correct. Hemophilia a, an xlinked bleeding disorder, results from mutations in the gene encoding coagulation factor viii.
Federal register human gene therapy for hemophilia. Obstacles and future of gene therapy for hemophilia. Technavios hemophilia gene therapy a pipeline analysis report, has been prepared based on an indepth market analysis with inputs from industry experts. Human gene therapy for hemophila draft guidance for industry. The report also includes a discussion of the key companies operating in this market. Valoctocogene roxaparvovec is gene therapy designed for the treatment of hemophilia a. Hemophilia b is an xlinked bleeding disorder that results from a deficiency or dysfunction of coagulation factor ix.
Pdf advances in gene therapy for hemophilia researchgate. Jul 23, 2019 hemophilia provides an attractive target for gene therapy studies, due to the monogenic nature of these disorders and easily measurable endpoints factor levels and bleed rates. Oct, 2017 technavios hemophilia gene therapy a pipeline analysis report, has been prepared based on an indepth market analysis with inputs from industry experts. In fact, multiple recent clinical trials have shown therapeutic, and. Hemophilia gene therapy is effective and safe blood. Update on clinical gene therapy for hemophilia blood. Gene therapy helps patients with hemophilia national. Hemophilia gene therapies have the potential to provide prolonged, highlevel expression of factor, and limit the need for frequent factor infusion. While gene therapy holds great potential for the treatment of hemophilia, it also faces some obstacles. The report covers the market landscape and its growth prospects during the forecast period. Our gene therapy product candidate etranacogene dezaparvovec amt061 consists of an aav5 viral vector carrying a gene cassette with the padua variant of factor ix fixpadua uniqure is now conducting the phase iii hopeb. The results highlighted knowledge gaps and educational needs related to gene therapy for hemophilia. In results from the sparkpfizer trial of gene therapy for hemophilia b treatment with spk9001 resulted in a mean steadystate fix coagulant activity of about 33 percent of normal two years after treatment. Researchers have scored their first clear success in using gene therapy to treat hemophilia, an.
The guidance document provides recommendations to stakeholders developing human gene therapy gt products for the treatment of hemophilia. The initiation of my own independent research career coincided with these landmark discoveries, and my research group, and many others, exploited. Hemophilia and gene therapy hemophilia occurs when the genes that are vital to producing clotting factors are faulty. Hemophilia provides an attractive target for gene therapy studies, due to the monogenic nature of these disorders and easily measurable endpoints factor levels and bleed rates. Adenoassociated virus aavmediated gene therapy has shown clinical benefit after 1 year of followup for patients with hemophilia a. Now, investigators report 2year and 3year safety and efficacy data from 15 patients with severe hemophilia a in a manufacturersponsored phase 12 doseescalation study involving a single infusion of the nonfda. Breakthroughs in gene therapy for hemophilia ash clinical news. Mar 31, 2017 the future of gene therapy for hemophilia looks bright. For preclinical research on gene therapy in hemophilia, several wellvalidated small and large hemophilic animal models are available. Jun 11, 2016 curing hemophilia would be a signal to the marketplace that gene therapy has hit prime time, says eric faulkner, who studies disruptive medicines at evidera, a consultancy. Hemophilia gene therapy a pipeline analysis report gii. Dec 06, 2017 gene therapy stops bleeding episodes in hemophilia trial.
Factor levels follow a sawtooth pattern that is seldom in the normal range and falls so low. Gene therapy stops bleeding episodes in hemophilia trial. Gene therapy, openlabel, doseescalation study of pf06838435 spk9001 adenoassociated viral vector with human factor ix gene in subjects with hemophilia b brief summary a phase 12, openlabel, nonrandomized, doseescalation study of spk9001 in subjects with hemophilia b. Results from this study represent a promising step toward making gene therapy a viable treatment option for hemophilia b. Human clinical trials are underway to test potential gene therapies for hemophilia. Our gene therapy product candidate etranacogene dezaparvovec amt061 consists of an aav5 viral vector carrying a gene cassette with the padua variant of factor ix fixpadua. Transferring a form of the gene for factor viii using a viral vector corrected plasma levels of the factor and stopped bleeding episodes for patients with severe hemophilia a, a study shows. Hemophilia is a genetic disease that prevents blood from clotting properly leading to prolonged internal and external bleeding. After many years, gene therapy in patients with hemophilia has started to show promising results in alleviating symptoms and improving the disease phenotype. Gene therapy frequently asked questions pdf gene therapy glossary pdf.
Advances and challenges for hemophilia gene therapy. The hemophilias are ideally suited for gene therapy because a small increment in blood factor levels. Pdf the xlinked bleeding disorder hemophilia causes frequent and exaggerated bleeding that can be lifethreatening if untreated. Hemophilia may be considered a low hanging fruit for gene therapy because a small increment in blood factor levels 2% of normal significantly improves the. Such therapy would reduce the need for longterm iv infusions of clotting factors. This collection of programs provides important information on the science behind gene therapy for hemophilia, the latest safety and efficacy data from clinical trials, and the potential. Pdf gene therapy provides hope for a cure for patients with haemophilia by establishing continuous endogenous expression of factor viii or factor ix. Hemophilia is an xlinked monogenic coagulation disorder resulting from a deficiency in coagulation factors in the intrinsic coagulation cascade. There are existing treatments for hemophilia that require lifelong administration, while gene therapy may offer a onetime treatment to.
The guidance provides recommendations on the clinical trial design and related development of coagulation factor viii hemophilia a and ix hemophilia b activity assays, including how to address. Human gene therapy for hemophilia draft guidance for industry this guidance document is for comment purposes only. Pdf using factor vii in hemophilia gene therapy bahram. The vector transduces hepatocytes, leading to the production of fix. Pfizer and spark therapeutics entered into a license agreement. Hemophilia has long been one of the disorders thought most likely to be correctible with gene therapy, but previous approaches to deliver the gene have been disappointing, says nhlbi acting director dr. Gene therapy information pdf there is excitement in the hemophilia community, both from the side of patients and from physicians and researchers, about the potential benefits of gene therapy for the health and quality of life of hemophiliacs.
Curing hemophilia would be a signal to the marketplace that gene therapy has hit prime time, says eric faulkner, who studies disruptive medicines at evidera, a consultancy. Hemophilia is due to a deficiency in a coagulation factor that results in the inability of the blood to clot efficiently. In hemophilia b gene therapy, either wildtype or padua factor ix with a liverspecific promoter is inserted into the genome of the aav vector and administered via a peripheral vein. This guidance provides recommendations on the clinical trial design and related development of coagulation factor viii hemophilia a and ix hemophilia b activity assays. Leap forward towards gene therapy cure for haemophilia a. It is the most common type of hemophilia and occurs much more frequently in males. One of the interventions for hemophilia currently being explored is gene therapy. Gene therapy for hemophilia explains the complex concepts that underlie gene therapy in simple terms, with colourful medical illustrations and a handy glossary to help explain terminology. Hemophilia is an xlinked bleeding disorder caused by deficiency of coagulation factor viii fviii or factor ix fix function due to mutations in the. Over the last two decades, a series of preclinical and earlyphase clinical studies on gene therapy for hemophilia have demonstrated an impressive amelioration of the disease phenotype, establishing the clinical potential of gene therapy for this disease. All successful, preclinical and clinical studies to date have utilized recombinant adenoassociated viral aav vectors for factor viii or ix hepatocyte transduction. Several ongoing studies are focused on evaluating various vectors for gene delivery, strategies to enhance transduction efficiency in human hepatocytes, definition of the immune and stress responses to vector administration, and the potential application of genome editing for the treatment. Takeda demonstrates its longstanding commitment to advancing. The future of gene therapy for hemophilia looks bright.
The best currently available treatments for hemophilia a and b factor viii or factor ix deficiency, respectively require frequent intravenous infusion of highly expensive proteins that have short halflives. Aav mediated gene therapy for hemophilia b is safe and efficacious. Hemophilia a is a genetic disease caused by the deficiency of clotting factor viii. Oct 01, 2018 hemophilia b, despite being far less common than hemophilia a, was initially a more attractive target for gene therapy from a molecular perspective. Now, investigators report 2year and 3year safety and efficacy data from 15 patients with severe hemophilia a in a manufacturersponsored phase 12 doseescalation study involving a single infusion of the nonfdaapproved therapy aav5hfviiisq. This study explored knowledge and perceptions about hemophilia gene therapy among the health care team and scientists. Investigational gene therapy for hemophilia is designed to add a functional copy of the factor viii or factor ix gene to the cells command center nucleus. She hails the trial and a second study into gene therapy for people with a resistant form of the rarer haemophilia b as leading the way to a cure for haemophilia. Advances in therapy gene therapy is currently being investigated as a treatment options for hemophiliacs. Gene therapy in patients with severe hemophilia a nejm. Both hemophilia a and b are caused by defects in single genes.
Conventional therapy requires frequent intravenous infusions of the missing coagulation protein factor viii fviii for hemophilia a and factor ix. To improve the clinical phenotype of hemophilia, prolonged highlevel expression of clotting factors is needed. This works by providing patients with hemophilia a new working copy of the genes for either factor viii or. Typically, the diseases are identical and, in both, only a modest amount of expression is required to produce a big benefit for the patient, dr.
Quick take gene therapy in patients with severe hemophilia a 02. Gene therapy for hemophilia is starting to come of age and promises to transform the way patients with this rare blood disease are treated. Dec 06, 2017 the hemophilia gene therapy is one of several being tested for conditions including sickle cell anemia and huntingtons disease. The genetic era in hemophilia began in the early 1980s with the isolation and characterization of the genes for human factor viii gitschier et al. The concept of gene therapy has sort of been at the. Hemophilia is a genetic blood clotting disorder where patients do not make enough of the factors that allow blood to clot. Gene therapy is an experimental treatment technique that uses genes or genetic material to treat or prevent disease. Confirmed that certain hemophilia a and hemophilia b gene mutations changes in the genes are linked to inhibitor development. The breakthrough in modern era gene therapy for hemophilia was the publication of the nathwani et al study in 2011. Mar 11, 2019 gene therapy for hemophilia is starting to come of age and promises to transform the way patients with this rare blood disease are treated. A gene therapy approach using a socalled antibodydrug conjugate adc conditioning regimen led to safe and sustained production of factor viii fviii in platelets, and prevented joint bleeding in a mouse model of hemophilia a, according to new research the study, nongenotoxic antibodydrug conjugate conditioning enables safe and effective platelet. In 2011, a study found adenovirusassociated virus vector expressing human factor ix gene increased fix levels in all participants with hemophilia b. Gene therapy for hemophilia article pdf available in hematologyoncology clinics of north america 315. This guidance is intended to assist stakeholders developing human gene therapy gt 1 products for the treatment of hemophilia.
Human gene therapy for hemophila draft guidance for. Submit one set of either electronic or written comments on this draft guidance by. Gene therapy for hemophilia a and b could be a permanent cure for people who have these rare, sometimes lifethreatening conditions. There are existing treatments for hemophilia that require lifelong administration, while gene therapy may offer a onetime treatment to address the cause of the disease.
581 1094 513 643 1171 334 746 1064 648 843 1069 173 792 1034 964 601 706 1177 316 113 1391 767 176 441 1206 887 823 1154 180 745 795 507 924